1. Role: Director. Scope: Department. Date: 2019.
Grant H. Skrepnek, Ph.D., R.Ph.
Professor
Pharmacy Clinical & Admin Sci
Phone (405) 271-6878 x47105
Fax (4050 271-6430
Office CPB 214
Email grant-skrepnek@ouhsc.edu
Summary
I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Research
Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Publications & Presentations
- 6. Tidmore L M, Skrepnek G H. Response: Letter to the Editor. Alzheimer Disease and Associated Disorders. 2023; 37 : 265-66
7. Dickson M C, Nguyen M M, Patel C, Graich S, Benson C, Cothran T, Skrepnek G H. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation. Advances in Therapy. 2023; 40 : 349-66
8. Rathbun C, Lewis M M, Yuet W C, Woo S, Miller J L, Skrepnek G H. The Medication Possession Ratio as a Predictor of Longitudinal HIV-1 Viral Suppression. The Annals of pharmacotherapy. 2023; 57 : 1264-1272
9. Boylan P, Skrepnek G, Neely S. Medication therapy problems assessment within medication history objective structured clinical examinations using standardized patients versus peer actors. Journal of the American College of Clinical Pharmacy. 2023; 6 : 354-362
10. Nguyen M M, Dickson M C, Skrepnek G H. Medicaid Value-Based Contract (VBC) in autoimmune diseases involving tumor necrosis factor. Oklahoma Health Care Authority. 2022
Grants
- 1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.
2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.
3. HIV Adherence Services. Start Date: 2022. End Date: 2023.
4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.
5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.
Awards and Honors
- 1. Academy of Managed Care Pharmacy Nexus 2022, National Harbor, MD, Oct. 11-14, 2022. Top Conference Poster (Student, Matthew C. Dickson). Date: 2022.
2. Academy of Managed Care Pharmacy. Bronze Recognition. Date: 2015.
3. International Symposium of the Diabetic Foot. Top Conference Podium. Date: 2015.
Education
no results
Administrative Assignments
2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.